News
Drugmaker Refuses FDA's Request to Pull Gene Therapy Tied to Patient Deaths
The agency also revoked Sarepta's platform technology designation for AAVrh74 Friday and issued a safety communication saying the agency was investigating the three deaths due to acute liver failure following treatment with Sarepta's AAVrh74 gene therapies.
Sarepta stands behind Elevidys after FDA requests gene therapy be pulled from market
As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head, the biotech is standing firm behind its approved Duchenne muscular dystrophy (DMD) treatment. | As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head,
MedPage Today on MSN17h
Gene Therapy May Hold Better Outcomes for Congenital Deafness Than Cochlear ImplantYouth with congenital deafness treated with gene therapy showed better progress on certain hearing measures than counterparts ...
Sarepta Therapeutics (NASDAQ:SRPT) said late Monday it will pause all shipments of its Duchenne muscular dystrophy gene ...
Groundbreaking new research shows that it is possible to use gene therapy to restore hearing in both children and adults.
Sarepta Therapeutics said on Monday that it will pause all shipments of its Elevidys gene therapy in the United States after a muscular dystrophy patient who received a different, experimental ...
Zacks Investment Research on MSN21h
SRPT Down After Third Death in Muscular Dystrophy Gene Therapy ProgramShares of Sarepta Therapeutics SRPT nosedived 35.9% on Friday following the death of a patient dosed with one of its ...
A team of Chinese medical experts say they can produce anti-cancer cells directly inside the human body using gene therapy ...
Massachusetts-based Sarepta Therapeutics, facing scrutiny from regulators, is reducing its global workforce by 36% in an ...
Our Bureau, Mumbai Friday, July 18, 2025, 17:45 Hrs [IST] ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback